Wajiha Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wajiha Shaikh has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ushna Zameer
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
3 shared publications Aariz Hussain
1 shared publication- Aariz Hussain
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
1 shared publication Anood Choudhary
Department of MBBS, Karachi Medical And Dental College, Karachi, Pakistan
1 shared publication- Areeba Fareed
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
1 shared publication - Rabia Qader
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
1 shared publication
Latest Publications
- 17 January 2025
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 194 (2) , 439-446
Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials (RCTs)
Objective This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn’s disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management. Methods A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients. Inclusion criteria focused on outcomes such as remission rates, C-reactive protein (CRP) levels, quality of life (QoL), and adverse events (AEs). Statistical analysis using RevMan 5.3 involved weighted mean differences (MD) and 95% confidence intervals to compare outcomes between the cannabis and control groups. Results The meta-analysis revealed significant findings regarding the impact of cannabis on CD management. The cannabis group exhibited significantly higher clinical remission rates at 8 weeks compared to the control group, with low heterogeneity [MD = − 67.98; 95% CI: (− 100.68, − 35.29)]. However, a statistically significant improvement in QoL was observed in the placebo group compared to the cannabis-treated group [MD = 19.62; 95% CI (14.24 to 25.00)]. There was a non-significant lowering in serum CRP levels compared to the placebo group [MD: − 0.51; 95% CI: (− 1.05, 0.02)]. Conclusion The study concludes that cannabis shows promise as a therapeutic option for CD, demonstrating higher remission rates and potential benefits for disease management. However, it also highlights the need for larger, standardized research studies to solidify conclusions regarding efficacy, safety, and biomarker responses in CD patients.
- 17 January 2025
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 194 (2) , 439-446
Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials (RCTs)
Objective This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn’s disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management. Methods A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients. Inclusion criteria focused on outcomes such as remission rates, C-reactive protein (CRP) levels, quality of life (QoL), and adverse events (AEs). Statistical analysis using RevMan 5.3 involved weighted mean differences (MD) and 95% confidence intervals to compare outcomes between the cannabis and control groups. Results The meta-analysis revealed significant findings regarding the impact of cannabis on CD management. The cannabis group exhibited significantly higher clinical remission rates at 8 weeks compared to the control group, with low heterogeneity [MD = − 67.98; 95% CI: (− 100.68, − 35.29)]. However, a statistically significant improvement in QoL was observed in the placebo group compared to the cannabis-treated group [MD = 19.62; 95% CI (14.24 to 25.00)]. There was a non-significant lowering in serum CRP levels compared to the placebo group [MD: − 0.51; 95% CI: (− 1.05, 0.02)]. Conclusion The study concludes that cannabis shows promise as a therapeutic option for CD, demonstrating higher remission rates and potential benefits for disease management. However, it also highlights the need for larger, standardized research studies to solidify conclusions regarding efficacy, safety, and biomarker responses in CD patients.
- 23 December 2023
- Published by SAGE Publications in Tumori Journal
- Vol. 110 (4) , 295-296
A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval
Cisplatin-based combos have become first-line treatment regimens in standard of care because of their high overall survival improvement. Despite being the first-line therapy, due to its side effects, roughly half of all patients suffering from Metastatic urothelial cancer are ineligible for it. To address this issue, scientists have been developing highly specific antibody-drug conjugates to address this issue. For locally advanced or metastatic bladder cancer, a combination of Padcev (enfortumab vedotin-ejfv) with pembrolizumab (Keytruda) has been authorized by the FDA as a first-line treatment and has shown promising outcomes in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations.
- 23 December 2023
- Published by SAGE Publications in Tumori Journal
- Vol. 110 (4) , 295-296
A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval
Cisplatin-based combos have become first-line treatment regimens in standard of care because of their high overall survival improvement. Despite being the first-line therapy, due to its side effects, roughly half of all patients suffering from Metastatic urothelial cancer are ineligible for it. To address this issue, scientists have been developing highly specific antibody-drug conjugates to address this issue. For locally advanced or metastatic bladder cancer, a combination of Padcev (enfortumab vedotin-ejfv) with pembrolizumab (Keytruda) has been authorized by the FDA as a first-line treatment and has shown promising outcomes in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations.
- Open Access
- 29 October 2023
- Published by Center for Open Science in PsyArXiv
Breakthrough In The Treatment Of Sleep-Paralysis: Meditation-Relaxation and Cognitive Behavioral Therapy
Sleep paralysis (SP) is a distressing phenomenon when individuals wake up during REM sleep, experiencing temporary muscle paralysis. Often accompanied by fear and hallucinations, sleep paralysis can significantly impact an individual's well-being. Around 7.6% of the population encounter sleep paralysis at least once, but the prevalence of isolated sleep paralysis is unclear due to research challenges and mental health stigma. This letter reviews current research on sleep paralysis and emphasizes non-pharmacological treatments like Cognitive-Behavioral Therapy (CBT) and Meditation-Relaxation (MR) therapy, showing promising results in managing episodes. A pilot study of MR therapy on narcolepsy patients revealed a significant reduction in SP episodes. However, more research on MR therapy for isolated sleep paralysis is necessary for better treatment strategies. Public education is vital in dispelling misconceptions and encouraging affected individuals to seek proper care and contribute to research, while addressing the stigma associated with sleep paralysis remains an ongoing necessity.
- 29 October 2023
- Published by Center for Open Science in PsyArXiv
Open AccessBreakthrough In The Treatment Of Sleep-Paralysis: Meditation-Relaxation and Cognitive Behavioral Therapy
Sleep paralysis (SP) is a distressing phenomenon when individuals wake up during REM sleep, experiencing temporary muscle paralysis. Often accompanied by fear and hallucinations, sleep paralysis can significantly impact an individual's well-being. Around 7.6% of the population encounter sleep paralysis at least once, but the prevalence of isolated sleep paralysis is unclear due to research challenges and mental health stigma. This letter reviews current research on sleep paralysis and emphasizes non-pharmacological treatments like Cognitive-Behavioral Therapy (CBT) and Meditation-Relaxation (MR) therapy, showing promising results in managing episodes. A pilot study of MR therapy on narcolepsy patients revealed a significant reduction in SP episodes. However, more research on MR therapy for isolated sleep paralysis is necessary for better treatment strategies. Public education is vital in dispelling misconceptions and encouraging affected individuals to seek proper care and contribute to research, while addressing the stigma associated with sleep paralysis remains an ongoing necessity.
- Open Access
- 1 April 2023
- Published by SAGE Publications in Rare Tumors
- Vol. 15
Letter re: Uveal melanoma metastasis to the liver: Unveiling effective strategies with HEPZATO KIT
- 1 April 2023
- Published by SAGE Publications in Rare Tumors
- Vol. 15
Open AccessLetter re: Uveal melanoma metastasis to the liver: Unveiling effective strategies with HEPZATO KIT